fluoxetine has been researched along with fentanyl in 17 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (5.88) | 18.2507 |
| 2000's | 8 (47.06) | 29.6817 |
| 2010's | 7 (41.18) | 24.3611 |
| 2020's | 1 (5.88) | 2.80 |
| Authors | Studies |
|---|---|
| Nagashima, R; Nishikawa, T; Tobita, M | 1 |
| Morphy, R; Rankovic, Z | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Abraham, MH; Acree, WE; Ibrahim, A | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| García-Mera, X; González-Díaz, H; Prado-Prado, FJ | 1 |
| Alelyunas, YW; Bui, K; Empfield, JR; McCarthy, D; Pelosi-Kilby, L; Shen, C; Spreen, RC | 1 |
| Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
| Johnson, BM; Meanwell, NA; Shu, YZ; Zhuo, X | 1 |
| Njo, L; Rich, JM; Roberts, KW; Smith, KP | 1 |
| Chambost, M; Combe, C; Liron, L; Peillon, D | 1 |
| Dimopoulos, NP; Gitsa, OE; Liappas, AI; Liappas, IA; Mellos, E; Rabavilas, AD | 1 |
| Kennedy, SE; Koeppe, RA; Young, EA; Zubieta, JK | 1 |
| Greenwald, MK | 1 |
| Larson, KJ; Nicholson, WT; Price, DL; Sprung, J; Weingarten, TN; Wittwer, ED | 1 |
| Naranjo, J; Pollard, EM; Sprung, J; Warner, MA; Warner, ME; Weingarten, TN | 1 |
| Alsaab, S; Cobb, C; Haidari, M; Mansani, S; Ponds, D; Romero, L | 1 |
1 review(s) available for fluoxetine and fentanyl
| Article | Year |
|---|---|
Designed multiple ligands. An emerging drug discovery paradigm.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Anti-Allergic Agents; Anti-Inflammatory Agents, Non-Steroidal; Antidepressive Agents; Antihypertensive Agents; Antipsychotic Agents; Chemistry, Pharmaceutical; Dopamine D2 Receptor Antagonists; Drug Design; Humans; Ligands; Metabolic Diseases; Peroxisome Proliferator-Activated Receptors; Receptors, Histamine H1; Selective Serotonin Reuptake Inhibitors | 2005 |
1 trial(s) available for fluoxetine and fentanyl
| Article | Year |
|---|---|
Dysregulation of endogenous opioid emotion regulation circuitry in major depression in women.
Topics: Adrenocorticotropic Hormone; Adult; Brain; Carbon Radioisotopes; Depressive Disorder, Major; Emotions; Female; Fentanyl; Fluoxetine; Humans; Hydrocortisone; Positron-Emission Tomography; Receptors, Opioid, mu; Selective Serotonin Reuptake Inhibitors; Sex Factors; Synaptic Transmission; Treatment Outcome | 2006 |
15 other study(ies) available for fluoxetine and fentanyl
| Article | Year |
|---|---|
A discriminant model constructed by the support vector machine method for HERG potassium channel inhibitors.
Topics: Animals; CHO Cells; Cricetinae; Discriminant Analysis; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Potassium Channel Blockers; Potassium Channels, Voltage-Gated | 2005 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Air to lung partition coefficients for volatile organic compounds and blood to lung partition coefficients for volatile organic compounds and drugs.
Topics: Air; Animals; Humans; Lung; Organic Chemicals; Probability; Rats; Tissue Distribution; Volatilization | 2008 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
Topics: Antiparasitic Agents; Molecular Structure; Neural Networks, Computer; Parasitic Diseases; Quantitative Structure-Activity Relationship; Species Specificity; Thermodynamics | 2010 |
Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.
Topics: Central Nervous System Agents; Drug Evaluation, Preclinical; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Solubility | 2010 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
Metabolic and Pharmaceutical Aspects of Fluorinated Compounds.
Topics: Drug Design; Fluorine; Halogenation; Humans; Pharmaceutical Preparations | 2020 |
Unusual hypotension and bradycardia in a patient receiving fenfluramine, phentermine, and fluoxetine.
Topics: Anesthesia, Conduction; Anesthetics, Intravenous; Appetite Depressants; Bradycardia; Drug Interactions; Fenfluramine; Fentanyl; Fluoxetine; Humans; Hypotension; Intraoperative Complications; Male; Middle Aged; Phentermine; Selective Serotonin Reuptake Inhibitors; Sympathomimetics | 1998 |
[Serotonin syndrome during fluoxetine poisoning in a patient taking moclobemide].
Topics: Adult; Anesthetics, Intravenous; Anti-Anxiety Agents; Antidepressive Agents; Antidepressive Agents, Second-Generation; Benzodiazepines; Female; Fentanyl; Fluoxetine; Humans; Moclobemide; Monoamine Oxidase Inhibitors; Neuromuscular Blockade; Neuromuscular Nondepolarizing Agents; Pancuronium; Respiration, Artificial; Selective Serotonin Reuptake Inhibitors; Serotonin Syndrome; Thiopental | 2000 |
Oral transmucosal abuse of transdermal fentanyl.
Topics: Administration, Cutaneous; Administration, Oral; Adult; Chronic Disease; Depressive Disorder; Drug Administration Schedule; Drug Therapy, Combination; Dysthymic Disorder; Female; Fentanyl; Fluoxetine; Greece; Humans; Mouth Mucosa; Pain; Pica; Polychondritis, Relapsing; Self Administration; Substance-Related Disorders | 2004 |
Behavioral economic analysis of drug preference using multiple choice procedure data.
Topics: Choice Behavior; Economics; Fentanyl; Fluoxetine; Hallucinogens; Humans; Hydromorphone; Injections, Intramuscular; Methadone; Models, Psychological; Motivation; N-Methyl-3,4-methylenedioxyamphetamine; Naltrexone; Narcotics; Psychotropic Drugs; Recreation; Selective Serotonin Reuptake Inhibitors; Substance Abuse, Intravenous; Substance-Related Disorders | 2008 |
Myoclonus in patient on fluoxetine after receiving fentanyl and low-dose methylene blue during sentinel lymph node biopsy.
Topics: Drug Interactions; Fentanyl; Fluoxetine; Humans; Male; Methylene Blue; Middle Aged; Myoclonus; Sentinel Lymph Node Biopsy; Serotonin Syndrome | 2015 |
Serotonergic medications, herbal supplements, and perioperative serotonin syndrome.
Topics: Aged; Curcuma; Dietary Supplements; Drug Interactions; Fentanyl; Fluoxetine; Humans; Male; Midazolam; Naloxone; Perioperative Period; Serotonin Agents; Serotonin Syndrome; Time Factors; Trazodone; Young Adult | 2017 |
Storage of urine specimens in point of care (POC) urine drug testing cups reduces concentrations of many drugs.
Topics: Amitriptyline; Chromatography, Liquid; Drug Storage; Fentanyl; Flunitrazepam; Fluoxetine; Humans; Mass Spectrometry; Nortriptyline; Paroxetine; Point-of-Care Testing; Sertraline | 2019 |